Literature DB >> 33715032

PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?

Laura Evangelista1, Pierpaolo Alongi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33715032     DOI： 10.1007/s00259-021-05295-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  6 in total

1.  10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients.

Authors:  Fabio Zattoni; Ilaria Ravelli; Marco Rensi; Decio Capobianco; Eugenio Borsatti; Tania Baresic; Agostino Chiaravalloti; Orazio Schillaci; Pierpaolo Alongi; Tommaso Vincenzo Bartolotta; Ilaria Rambaldi; Mirco Bartolomei; Mohsen Farsad; Manuel Tredici; Davide Donner; Franca Chierichetti; Giuseppe Trifirò; Elisabetta Brugola; Marta Burei; Fabrizio Dal Moro; Diego Cecchin; Laura Evangelista
Journal:  Clin Nucl Med       Date:  2020-08       Impact factor: 7.794

2.  Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.

Authors:  Bernhard Grubmüller; Sazan Rasul; Pascal Baltzer; Harun Fajkovic; David D'Andrea; Florian Berndl; Agnes Maj-Hes; Karl Hermann Grubmüller; Markus Mitterhauser; Wolfgang Wadsak; Sarah Pfaff; Shahrokh F Shariat; Marcus Hacker; Gero Kramer; Markus Hartenbach
Journal:  Prostate       Date:  2019-10-15       Impact factor: 4.104

3.  Future patient care in Kansas.

Authors:  O E Ebel
Journal:  J Kans Med Soc       Date:  1969-06

4.  Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.

Authors:  Sofia Vaz; Boris Hadaschik; Michael Gabriel; Ken Herrmann; Matthias Eiber; Durval Costa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01       Impact factor: 9.236

5.  Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer.

Authors:  Laura Evangelista; Maria Giuseppina Bonavina; Emilio Bombardieri
Journal:  Nucl Med Biol       Date:  2017-04-05       Impact factor: 2.408

6.  (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.

Authors:  Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Riccardo Schiavina; Riccardo Renzi; Marco Borghesi; Piergiorgio Di Tullio; Eugenio Brunocilla; Andrea Ardizzoni; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-01       Impact factor: 9.236
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.